Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BlossomHill TherapeuticsBLSM 8 Cash-to-Debt is 6.10 as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100. Among 1,396 Biotechnology companies, BlossomHill Therapeutics ranks worse than 71633.17% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BlossomHill Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2025 was 6.10.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BlossomHill Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for BlossomHill Therapeutics's Cash-to-Debt or its related term are showing as below:
BLSM's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 6.21 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
BlossomHill Therapeutics Cash-to-Debt Related Terms
BlossomHill Therapeutics Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BlossomHill Therapeutics Cash-to-Debt Chart
BlossomHill Therapeutics Annual Data
Trend
Dec24
Dec25
Cash-to-Debt
190.76
6.10
BlossomHill Therapeutics Semi-Annual Data
Dec24
Dec25
Cash-to-Debt
190.76
6.10
BLSM vs : Cash-to-Debt Comparison
For the Biotechnology subindustry, BlossomHill Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BlossomHill Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BlossomHill Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where BlossomHill Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics (BLSM) has a Cash-to-Debt of 6.10 as of Dec. 2025. According to the industry distribution chart, BlossomHill Therapeutics ranks #999999 out of 1396 companies in the Biotechnology industry.
Is BlossomHill Therapeutics' Cash-to-Debt too high?
BlossomHill Therapeutics' current Cash-to-Debt is 6.10. The Biotechnology industry median Cash-to-Debt is 6.21. BlossomHill Therapeutics' value of 6.10 is 1.8% below this industry median. Based on the distribution chart, BlossomHill Therapeutics ranks #999999 out of 1396 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Cash-to-Debt compare to ?
According to the Biotechnology industry distribution chart, BlossomHill Therapeutics ranks #999999 out of 1396 companies for Cash-to-Debt. This places BlossomHill Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.21. BlossomHill Therapeutics' value of 6.10 is 1.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.21, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BlossomHill Therapeutics's current Cash-to-Debt of 6.10 is 1.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BlossomHill Therapeutics's current Cash-to-Debt is 6.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Cash-to-Debt of 6.10. The current Cash-to-Debt is 6.10 and 1.8% below the Biotechnology industry median of 6.21. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Cash-to-Debt is 6.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score
Get the complete analysis for BLSM
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLSM has been successfully added to your 
